CKPT

Checkpoint Therapeutics, Inc.

1.77 USD
-0.11 (-5.85%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Checkpoint Therapeutics, Inc. stock is up 21.23% since 30 days ago. The next earnings date is Aug 12, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 42.86% of the previous 6 May’s closed higher than April. In the last 1 Unusual Options Trades, there were 1 PUT. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
19 Apr 16:25 19 Apr, 2024 2.50 PUT 400 1110

About Checkpoint Therapeutics, Inc.

Checkpoint Therapeutics, Inc. focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients.